A grave outcome of posterior reversible encephalopathy syndrome in a patient receiving avastin (Bevacizumab) for metastatic high-grade serous ovarian cancer

5Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A 45-year-old female developed neurological symptoms and elevated diastolic blood pressure while on bevacizumab (Avastin) and gemcitabine for recurrent carboplatin-resistant high-grade serous ovarian cancer. A brain MRI diagnosed our patient with posterior reversible encephalopathy syndrome. We are discussing her presenting symptoms in this paper as well as the management and the outcome. We emphasize the importance of keeping this rare but very serious complication in all patients receiving bevacizumab.

Cite

CITATION STYLE

APA

Elmalik, H. H., Elazzazy, S., Salem, K. S., & Bujassoum, S. (2015). A grave outcome of posterior reversible encephalopathy syndrome in a patient receiving avastin (Bevacizumab) for metastatic high-grade serous ovarian cancer. Case Reports in Oncology, 8, 290–294. https://doi.org/10.1159/000435805

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free